Researchers have identified the AURKA/PHB2 signaling axis as a driver of acquired resistance to KRAS G12C inhibitors in non-small cell lung cancer. The study, published in 2026, reports that this pathway contributes to therapeutic escape and points to potential combination strategies designed to counter resistance rather than only blocking the primary KRAS mutation. The mechanistic findings may support next steps in preclinical validation and guide biomarker-led trial designs that incorporate resistance pathway monitoring. For the KRAS G12C space, the update is another datapoint that resistance is multi-determined and may require pathway-level intervention.